Participated in Cyted Health's $44M Series B led by EQT Life Sciences.
Cyted Health delivers a diagnostic platform that combines minimally invasive cell collection with high-resolution molecular analysis to detect early biological changes associated with Barrett’s esophagus and esophageal cancer
Cyted Health delivers a diagnostic platform that combines minimally invasive cell collection with high-resolution molecular analysis to detect early biological changes associated with Barrett’s esophagus and esophageal cancer.